department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

calendar

6 catalysts · 4,970 phase readout · 2,346 8k filing · 287 earnings · 274 pdufa · 129 phase 2 completion · 61 phase 1 completion

★ save view ↓export CSV

next 91 dayslessmore

MonWedFri

view

sort

soonest latest type sponsor alpha

type: device recall×type: patent expiry×clear all

search

type

phase readout4,970
8k filing2,346
earnings287
pdufa274
phase 2 completion129
phase 1 completion61

phase 1 initiation

32

phase 1 2 completion28

phase 0 trial completion22

phase 2 initiation16

therapy area

Infectious Disease6

Week of Apr 27, 2026

6

›Apr 28, 2026patent expiry91d agoGSK plc — dolutegravir sodium ODT (Constraining Patent Expiry (Japan))dolutegravir sodium

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →dolutegravir sodium →source: globaldata

›Apr 28, 2026patent expiry91d agoGSK plc — (abacavir sulfate + dolutegravir sodium+ lamivudine) ODT (Constraining Patent Expiry (Japan))(abacavir sulfate + dolutegravir sodium + lamivudine)

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →(abacavir sulfate + dolutegravir sodium + lamivudine) →source: globaldata

›Apr 28, 2026patent expiry91d agoGSK plc — cabotegravir sodium (Constraining Patent Expiry (US))cabotegravir sodium

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir sodium →source: globaldata

›Apr 28, 2026patent expiry91d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Constraining Patent Expiry (US))cabotegravir + rilpivirine LA

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir + rilpivirine LA →source: globaldata

›Apr 28, 2026patent expiry91d agoViiV Healthcare UK Ltd — cabotegravir LA (Constraining Patent Expiry (US))cabotegravir LA

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir LA →source: globaldata

›Apr 30, 2026patent expiry89d agoBasilea Pharmaceutica Ltd — isavuconazonium sulfate (Constraining Patent Expiry (US))isavuconazonium sulfate

Therapy area: Infectious Disease. Indication: Aspergillosis, Candidiasis, Cryptococcal Meningitis, Cryptococcosis, Zygomycosis (Mucormycosis)

full page →isavuconazonium sulfate →source: globaldata

$GSK51.35+1.20%

$GSK51.35+1.20%

$GSK51.35+1.20%